Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Gilead Sciences Inc. GILD

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition...

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:GILD)

Fundamentals Snapshot (NDAQ:GILD)

Current News (NDAQ:GILD)

Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines

Business Wire 5 days ago

Gilead Sciences Completes Acquisition of MiroBio

Business Wire 7 days ago

Kite's CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Business Wire 11 days ago

CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19

Business Wire 11 days ago

WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline

Business Wire 12 days ago

Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity

Business Wire September 13, 2022

Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study

Business Wire September 7, 2022

Kite's CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

Business Wire September 6, 2022

New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status

Business Wire September 4, 2022

Bullboard Posts (NDAQ:GILD)

roughly $80 billion biopharmaceutical company

The wide array of offerings helps fuel consistent payouts to shareholders. Current distributions are 73 cents per quarter, up 70% from 43...
jonathanS - August 3, 2022

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent

Rebecca - July 15, 2022

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

<< View Post To Watch Video >>
Rebecca - June 3, 2022

FSD Pharma Files Investigational New Drug Application “IND”

Rebecca - June 1, 2022

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

Rebecca - May 10, 2022

Lucid-MS for Multiple Sclerosis Treatment

<< View Post To Watch Video >>
Rebecca - May 3, 2022